Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/19 12:10:48 am
0.45 AUD   -1.10%
2021Immutep Taps Northway Biotech To Manufature Autoimmune Drug IMP761
MT
2021IMMUTEP : Advances IMP761 Manufacturing - Form 6-K
PU
2021Immutep Limited Advances IMP761 Manufacturing
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : AGM 2021 - CEO's presentation

11/25/2021 | 06:30pm EST

2021 AGM Presentation

Marc Voigt, CEO

The global leader in developing LAG-3 therapeutics

Notice: Forward-Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been

independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be

construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This presentation was authorised for release by the CEO, Marc Voigt.

General Overview

FY21 saw Immutep transform into a late-stage biotech with more trials,

partners and industry momentum than ever

Global leadership

Exciting potential of

Strengthened

position in LAG-3

lead product

partnerships &

with 4 LAG-3 related

candidate efti as a

collaborations with

product candidates

combination therapy

large pharma

in immuno-oncology

following compelling

industry leaders

and autoimmune

clinical data & strong

disease

rationale to combine

with multiple FDA

approved treatments

LAG-3 Pioneer: French immunologist

Prof Frédéric Triebel, Immutep CMO & CSO

LAG-3 is a validated immune checkpoint

Existing approved immuno-oncology therapies target:

PD-1 &

PD-L1CTLA-4

e.g.e.g.

LAG-3 was validated by BMS in a Phase III trial (ASCO 2021)

Immutep is positioned to lead in LAG-3 with more LAG-3 related programs than any other pharma or biotech

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immutep Ltd. published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2021 23:29:02 UTC.


ę Publicnow 2021
All news about IMMUTEP LIMITED
2021Immutep Taps Northway Biotech To Manufature Autoimmune Drug IMP761
MT
2021IMMUTEP : Advances IMP761 Manufacturing - Form 6-K
PU
2021Immutep Limited Advances IMP761 Manufacturing
CI
2021Immutep Signs Deal for Clinical Trial Production of Autoimmune Drug
MT
2021IMMUTEP : Advances IMP761 Manufacturing
PU
2021IMMUTEP : Amended Constitution
PU
2021Immutep Limited Announces Change of Registered Office Address, Effective 15 December 20..
CI
2021IMMUTEP : Change in substantial holding
PU
2021IMMUTEP : REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI ..
PU
2021Immutep Doses First Five Patients in Study of Triple Combination Cancer Treatment, Find..
MT
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 3,50 M 2,52 M 2,52 M
Net income 2022 -38,6 M -27,7 M -27,7 M
Net cash 2022 78,5 M 56,4 M 56,4 M
P/E ratio 2022 -7,07x
Yield 2022 -
Capitalization 389 M 279 M 279 M
EV / Sales 2022 88,6x
EV / Sales 2023 119x
Nbr of Employees -
Free-Float -
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,46 AUD
Average target price 1,17 AUD
Spread / Average Target 157%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED-7.14%279
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707